Earnings ·
Cytek Biosciences reports Q3 revenue of $53.2M and narrows full-year guidance to $208M-$211M
CTKBCytek Biosciences, Inc.
Cytek Biosciences reported third-quarter 2026 total revenue of $53.2 million, a 2% increase year-over-year, driven by strong U.S. demand for high-end instruments and service growth. GAAP gross margin expanded to 59%, up from 53% in the prior-year period, while operating expenses rose 8% to $39.6 million due to higher general and administrative costs, including litigation-related expenses. The company posted a net loss of $6.1 million compared to $5.5 million in the same quarter last year. Management maintained its full-year revenue guidance midpoint and narrowed the range to $208 million–$211 million. Cytek Biosciences is a leading cell analysis solutions company providing high-resolution tools for research use.